Facebook
Twitter
Telegram
Report an ErrorG1 Therapeutics Balance Sheet 2011-2024 | GTHX
Annual Balance Sheet G1 Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
19.1 M | -87.8 M | -214 M | -187 M | -259 M | -369 M | -104 M | -47.3 M | -22.9 M | - | - | - | - |
Long Term Debt |
50 M | 5.62 M | 6.75 M | 19.9 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.28 M | 1.14 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 9.54 M | 88 K | 79 K | - | - | - | - | - | - |
Total Current Liabilities |
29.7 M | 35.6 M | 27.6 M | 23.4 M | 19.8 M | 12.4 M | 11.7 M | - | - | - | - | - | - |
Total Liabilities |
86.2 M | 119 M | 111 M | 51.2 M | 29.3 M | 12.4 M | 11.8 M | 5.63 M | 2.17 M | - | - | - | - |
Deferred Revenue |
620 K | 7 K | 31 K | 237 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-780 M | -732 M | -584 M | -436 M | -337 M | -214 M | -129 M | -65 M | -31.7 M | - | - | - | - |
Total Assets |
122 M | 188 M | 254 M | 229 M | 285 M | 371 M | 105 M | 48.2 M | 23.9 M | - | - | - | - |
Cash and Cash Equivalents |
32.2 M | 94.6 M | 221 M | 207 M | 269 M | 369 M | 104 M | 47.3 M | 22.9 M | - | - | - | - |
Book Value |
35.4 M | 68.7 M | 144 M | 177 M | 256 M | 359 M | 93.4 M | 42.6 M | 21.7 M | - | - | - | - |
Total Shareholders Equity |
35.4 M | 68.7 M | 144 M | 177 M | 256 M | 359 M | 93.4 M | -65 M | -31.7 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet G1 Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
37.1 M | 51.6 M | 50 M | 50 M | 75 M | 5.62 M | 75 M | - | 75 M | 6.75 M | 30 M | 30 M | 30 M | 20 M | 20 M | 20 M | 7.86 M | 9.54 M | 9.54 M | 9.54 M | 9.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
74.3 M | 86.2 M | 90.1 M | 90.3 M | 117 M | 119 M | 121 M | - | 118 M | 111 M | 65.2 M | 63.6 M | 63.1 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 5.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
396 K | 620 K | 686 K | 143 K | 505 K | 7 K | 9 K | - | 17 K | 31 K | 26 K | 185 K | 154 K | 237 K | 237 K | 237 K | 237 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-790 M | -780 M | -769 M | -751 M | -760 M | -732 M | -698 M | - | -634 M | -584 M | -544 M | -502 M | -463 M | -436 M | -436 M | -436 M | -436 M | -337 M | -337 M | -337 M | -337 M | -214 M | -214 M | -214 M | -214 M | -129 M | -129 M | -129 M | -129 M | -65 M | -65 M | -65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
102 M | 122 M | 133 M | 148 M | 162 M | 188 M | 167 M | - | 218 M | 254 M | 243 M | 277 M | 309 M | 229 M | 229 M | 229 M | 229 M | 285 M | 285 M | 285 M | 285 M | 371 M | 371 M | 371 M | 371 M | 105 M | 105 M | 105 M | 105 M | 48.2 M | 48.2 M | 48.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.9 M | 32.2 M | 52.6 M | 55.9 M | 68.2 M | 94.6 M | 93.2 M | - | 183 M | 221 M | 212 M | 244 M | 279 M | 207 M | 207 M | 207 M | 207 M | 269 M | 269 M | 269 M | 269 M | 369 M | 369 M | 369 M | 369 M | 104 M | 104 M | 104 M | 104 M | 47.3 M | 47.3 M | 47.3 M | - | 22.9 M | - | - | - | 3.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
27.7 M | 35.4 M | 43 M | 57.5 M | 45 M | 68.7 M | 46 M | - | 100 M | 144 M | 178 M | 213 M | 245 M | 177 M | 177 M | 177 M | 177 M | 256 M | 256 M | 256 M | 256 M | 359 M | 359 M | 359 M | 359 M | 93.4 M | 93.4 M | 93.4 M | 93.4 M | 42.6 M | 48.2 M | 48.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
27.7 M | 35.4 M | 43 M | 57.5 M | 45 M | 68.7 M | 46 M | 66.3 M | 100 M | 144 M | 178 M | 213 M | 245 M | 177 M | 177 M | 177 M | 177 M | 256 M | 256 M | 256 M | 256 M | 359 M | 359 M | 359 M | 359 M | 93.4 M | 93.4 M | 93.4 M | 93.4 M | -65 M | -65 M | -65 M | - | -31.7 M | - | - | - | -10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency